PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 161 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $273,000 | -34.8% | 71,758 | -12.7% | 0.11% | +64.7% |
Q4 2019 | $419,000 | +34.3% | 82,233 | +33.1% | 0.07% | +7.9% |
Q3 2019 | $312,000 | -22.4% | 61,773 | -5.3% | 0.06% | -25.9% |
Q2 2019 | $402,000 | +48.3% | 65,214 | +1.1% | 0.08% | +84.8% |
Q4 2018 | $271,000 | -16.9% | 64,532 | +24.1% | 0.05% | +35.3% |
Q3 2018 | $326,000 | -55.0% | 51,998 | -42.3% | 0.03% | -94.7% |
Q2 2018 | $725,000 | -33.9% | 90,177 | -39.4% | 0.64% | +333.1% |
Q3 2017 | $1,096,000 | +8.4% | 148,929 | 0.0% | 0.15% | -2.0% |
Q2 2017 | $1,011,000 | -7.1% | 148,929 | +29.2% | 0.15% | -22.2% |
Q1 2017 | $1,088,000 | +20.9% | 115,300 | +10.6% | 0.19% | -27.9% |
Q4 2016 | $900,000 | +5.0% | 104,213 | -23.0% | 0.27% | -35.0% |
Q3 2016 | $857,000 | +71.7% | 135,340 | +14.4% | 0.41% | +11.9% |
Q2 2016 | $499,000 | +10.2% | 118,285 | +13.9% | 0.37% | -40.7% |
Q1 2016 | $453,000 | -28.8% | 103,807 | 0.0% | 0.62% | -64.3% |
Q4 2015 | $636,000 | – | 103,807 | – | 1.75% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |